Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

A 28-year-old Middle Eastern man develops severe motor disturbances, including muscle rigidity, tremors, a parkinsonian gait, and involuntary, jerky limb movements, following the administration of a 3 ...

Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. | Intra-Cellular ...

Operator Hello, and welcome to the Q3 2024 Teva Pharmaceuticals Industries Limited earnings conference call. My name is Alex, ...

Detailed price information for Intra-Cellular Ther (ITCI-Q) from The Globe and Mail including charting and trades.

Background: Therapeutic options for patients with treatment-resistant schizophrenia are limited, and combination treatment with atypical antipsychotic drugs is an often used strategy. We tested ...

Medications assessed as independent variables were conventional antipsychotics, atypical antipsychotics, selective serotonin-reuptake inhibitors, tricyclic antidepressants, atypical ...

Data presented at Psych Congress 2024 showed improvements in social functioning and quality of life over an eight-week ...

These symptoms are sometimes treated with atypical antipsychotics. RLS is a movement disorder that involves strange sensations and involuntary leg movements as you sleep or when you’re in a relaxed ...

TJK Investigational Olanzapine Long-Acting Injectable Teva presented positive data from the initial period of the Phase 3 SOLARIS ...

Addition of the antipsychotic lumateperone (Caplyta) to an existing antidepressant improved symptoms of depression in a ...